Relmada Therapeutics, Inc. RLMD Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s accounts payable?
- Relmada Therapeutics, Inc. (RLMD) reported accounts payable of $1.76M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s accounts payable changed year-over-year?
- Relmada Therapeutics, Inc.'s accounts payable increased by 161.5% year-over-year, from -$2.87M to $1.76M.
- What does accounts payable mean?
- Represents the net change in obligations owed to suppliers and vendors for goods and services received. An increase indicates a source of cash through delayed payment, while a decrease represents a use of cash to settle liabilities.